Could a cold virus drug shield COPD lungs?

NCT ID NCT06149494

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 32 times

Summary

This study tested an experimental drug called vapendavir in 52 adults with COPD (a chronic lung disease). The goal was to see if the drug could reduce severe cold symptoms caused by rhinovirus, a common cold virus. Participants were given either vapendavir or a placebo and monitored for six weeks. The drug aims to stop the virus from multiplying, but it is not yet approved by the FDA.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • St. Mary's Hospital - Imperial College Respiratory Research Unit (ICRRU)

    London, W2 1NY, United Kingdom

Conditions

Explore the condition pages connected to this study.